-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 10, the NMPA official website showed that Hisun Pharmaceutical’s infliximab biosimilar entered the administrative approval stage and is expected to be approved in the near future
Infliximab is a human-mouse chimeric monoclonal antibody that specifically blocks tumor necrosis factor (TNF-α) developed by Johnson & Johnson / Merck.
The drug was first approved by the FDA for marketing in the United States in 1998, and was approved for marketing in Europe the following year.
Although it has been on the market in China for many years, the first infliximab biosimilar was only approved in July this year, from Taizhou Maibotec Pharmaceuticals
From Insight database (http://db.
Among several TNF-α antibody drugs, adalimumab has the most fierce competition as the "drug king".
From Insight database (http://db.
Biosimilars have not been optimistic about the recent threat of centralized procurement